Bluebird Bio has entered a strategic collaboration with Celgene to discover, develop and commercialize disease-altering gene therapies in oncology focused on genetically modifying T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells. Bluebird will be responsible for R&D through Phase I studies, at which point Celgene has an option to license any products resulting from the collaboration.   Financial terms include an undisclosed upfront payment and as ...